Date: 2016-03-07
Type of information: Nomination
Compound:
Company: Myokardia (USA - CA)
Therapeutic area: Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 7, 2016, MyoKardia announced the addition of Sunil Agarwal, M.D., to its board as an independent director. Dr. Agarwal is executive vice president and chief medical officer at Ultragenyx Pharmaceutical, where he leads the company's clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology and toxicology. Previously, Dr. Agarwal served in various leadership roles for more than a decade at Genentech. At Genentech, Dr. Agarwal was senior vice president and global head of clinical development for ophthalmology, metabolism, neurosciences, immunology and infectious diseases. His experience includes both development and medical affairs roles at MedImmune and Guilford Pharmaceuticals. Dr. Agarwal obtained a B.S. in neurobiology at Cornell University, and earned his M.D. from Tufts University School of Medicine. MyoKardia also announced that two senior leaders have joined the company to strengthen areas key to its development programs and product pipeline. Michael Graziano, Ph.D., is MyoKardia’s vice president, biology, leading the company’s biology research and translational medicine efforts to deliver on our preclinical pipeline strategy. Dr. Graziano is a member of MyoKardia’s executive committee. Previously, Dr. Graziano was an executive director in cardiovascular discovery at Merck Research Laboratories. His more than 25 years in cardiovascular and metabolic disease drug discovery and development include roles of increasing responsibility both at Merck and the Schering-Plough Research Institute. He is also a founder of The Institute for Life Science Entrepreneurship, a not-for-profit organization that fosters the creation of life science startups. Dr. Graziano holds a Ph.D. in pharmacology from the State University of New York, Stony Brook, and a B.A. in biology from New York University. He completed postdoctoral training in pharmacology at the University of Texas Southwestern Medical Center. Lisa Alaimo is vice president and program team leader for MyoKardia’s dilated cardiomyopathy program, as well as MyoKardia’s collaboration with Sanofi. The alliance of the two companies, one of the largest research and development commitments in genetic forms of cardiomyopathy, encompasses three major development programs at MyoKardia. Ms. Alaimo has served in project and strategic product development leadership roles at Portola Pharmaceuticals, Cor Therapeutics and Millennium Pharmaceuticals. She holds a B.S. in genetics and biochemistry from University of California, Davis.
Financial terms:
Latest news:
